MLICM
ODT

Metropolitan Life Insurance Company (MetLife)’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio ODT Stock Details ODT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-4,285
Closed -$181K – 2605
2020
Q2 		$181K Sell
4,285
-28
-0.6% -$906 ﹤0.01% 1867
2020
Q1 		$119K Hold
4,313
– – ﹤0.01% 1918
2019
Q4 		$140K Hold
4,313
– – ﹤0.01% 2140
2019
Q3 		$112K Buy
4,313
+3,663
+564% +$123K ﹤0.01% 2239
2019
Q2 		$23.8K Buy
+650
New +$15.6K ﹤0.01% 2583

Other funds holding ODT

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s ODT Position: Q3 2020 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Odonate Therapeutics, Inc. Common Stock (ODT) in Q3 2020, closing a stake of 4,285 shares — an estimated $181K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in ODT in Q2 2019 and held it in 5 quarters. The position peaked at $181K in Q2 2020. 89 funds tracked by Wall St. Rank hold ODT as of Q3 2020.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Odonate Therapeutics, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 4,285 Odonate Therapeutics, Inc. Common Stock shares in Q3 2020, an estimated $181K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Odonate Therapeutics, Inc. Common Stock in Q2 2019 and held it in 5 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Odonate Therapeutics, Inc. Common Stock position peaked at $181K in Q2 2020.
  • 89 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q3 2020.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q3 2020, filed 13 Nov 2020.